HHS Continues Key Biodefense Activities Amid Government Shutdown

On September 9, 2026, the U.S. Department of Health and Human Services (HHS) released a detailed shutdown contingency plan addressing how various biodefense and pandemic countermeasure activities will be handled in the event of a funding lapse. The plan explicitly highlights which programs will remain operational, including research and development, procurement, and stockpile management under the Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA), among others.

This contingency plan serves as a crucial framework for contractors engaged in biodefense and medical countermeasure initiatives. It establishes a path for continuity of certain funded activities, allowing essential projects to proceed even in the face of a government shutdown. Importantly, this does not equate to an announcement of new solicitations or guarantee of award for any upcoming contracts, thus highlighting the necessity for contractors to remain vigilant about their standing arrangements and the specific terms associated with their contracts.

The implications for contractors involved in these sectors are notable. The potential suspension of some functions, particularly those relating to Freedom of Information Act (FOIA) processing and specific evaluation and reporting mandates, may impact transparency and operational oversight. As it stands, contractors must take proactive steps to ascertain which aspects of their contracts and arrangements are slated for continuation and which may face delays or interruptions.

Companies engaged with HHS programs and dealing with the CDC and other relevant agencies must communicate with the appropriate HHS departments to confirm the status of their activities. Different types of contract-management functions may be partially or fully paused, making it essential for firms to be prepared for variations in operational capability.

For contractors in the medical countermeasure or biodefense sectors, it is also critical to understand that while some work may be allowed to proceed, not all contracts or administrative activities can be taken for granted. The uncertainty of the political landscape necessitates a careful review of current contracts and clear communication with agency representatives to ensure alignment with ongoing operations. The continuation plan serves as both a guideline for what may remain active and a signal of the importance placed on these vital public health initiatives, even amid budgetary constraints.

In summary, the HHS's shutdown contingency plan has outlined the potential continuity for key biodefense work, providing some assurance to contractors looking at the procurement landscape during uncertain times. Nevertheless, the lack of specific opportunities, contract values, or deadlines does create a level of ambiguity that firms need to navigate strategically while fostering clear communication with HHS.